公开(公告)号：US20080234384A1

公开(公告)日：2008-09-25

申请号：US12051741

申请日：2008-03-19

Applicant: Mikhail Chafeev ,  Nagasree Chakka ,  Jean-Jacques Cadieux ,  Jianmin Fu ,  Rajender Kamboj ,  Vishnumurthy Kodumuru ,  Jonathan Langille ,  Shifeng Liu ,  Jianyu Sun ,  Serguei Sviridov ,  Zaihui Zhang

Inventor： Mikhail Chafeev ,  Nagasree Chakka ,  Jean-Jacques Cadieux ,  Jianmin Fu ,  Rajender Kamboj ,  Vishnumurthy Kodumuru ,  Jonathan Langille ,  Shifeng Liu ,  Jianyu Sun ,  Serguei Sviridov ,  Zaihui Zhang

IPC: A61K31/166 ,  C07C335/32 ,  A61K31/155 ,  C07C257/00 ,  C07C279/04 ,  C07C233/78

CPC classification number: C07D333/34 ,  C07C323/44 ,  C07C323/62 ,  C07C335/16 ,  C07C335/32 ,  C07D333/38

Abstract: This invention is directed to compounds of formula (I): wherein m, n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

Abstract translation: 本发明涉及式（I）化合物：其中m，n，R 1，R 2和R 3如本文所定义 ，作为立体异构体，其对映体，互变异构体或其混合物; 或其药学上可接受的盐，溶剂合物或前药，用于治疗铁疾病。 本发明还涉及包含该化合物的药物组合物和使用该化合物治疗铁疾病的方法。

公开(公告)号：US20080234327A1

公开(公告)日：2008-09-25

申请号：US12053187

申请日：2008-03-21

Applicant: Jean-Jacques Cadieux ,  Jianmin Fu ,  Rajender Kamboj ,  Zaihui Zhang

Inventor： Jean-Jacques Cadieux ,  Jianmin Fu ,  Rajender Kamboj ,  Zaihui Zhang

IPC: A61K31/4439 ,  C07D401/04 ,  C07D417/04 ,  A61K31/427 ,  A61K31/4184 ,  C07D403/04 ,  A61P43/00

CPC classification number: C07D401/12

Abstract: This invention is directed to compounds of formula (I): wherein m, R1, R2, R3 and R4 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

Abstract translation: 本发明涉及式（I）化合物：其中m，R 1，R 2，R 3和R 4 本文定义为立体异构体，对映异构体，互变异构体或其混合物; 或其药学上可接受的盐，溶剂合物或前药，用于治疗铁疾病。 本发明还涉及包含该化合物的药物组合物和使用该化合物治疗铁疾病的方法。

公开(公告)号：US20080096895A1

公开(公告)日：2008-04-24

申请号：US11575640

申请日：2005-09-20

Applicant: Rajender Kamboj ,  Zaihui Zhang ,  Jian-Min Fu

Inventor： Rajender Kamboj ,  Zaihui Zhang ,  Jian-Min Fu

IPC: A61K31/496 ,  A61K31/497 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10 ,  C07D401/14 ,  C07D403/14 ,  C12N9/99

CPC classification number: A61K31/496 ,  A61K31/501

Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, V R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Abstract translation: 公开了在哺乳动物，优选人中治疗SCD介导的疾病或病症的方法，其中所述方法包括向有需要的哺乳动物施用式（I）化合物：其中x，y，G，J，K ，L，M，VR 2，R 3，R 4，R 5，R 5a R 6，R 6，R 6，R 7，R 7a，R 8， ＆lt; 8a＆gt;和＆lt; 8a＆gt;在本文中定义。 还公开了包含式（I）化合物的药物组合物。

公开(公告)号：US20070299081A1

公开(公告)日：2007-12-27

申请号：US11575639

申请日：2005-09-20

Applicant: Rajender Kamboj ,  Zaihui Zhang ,  Jianmin Fu ,  Serguei Sviridov ,  Shaoyi Sun ,  Mehran Seid Bagherzadeh ,  Vandna Raina ,  Duanjie Hou ,  Sultan Chowdhury ,  Shifeng Liu ,  Vishnumurthy Kodumuru ,  Nagasree Chakka

Inventor： Rajender Kamboj ,  Zaihui Zhang ,  Jianmin Fu ,  Serguei Sviridov ,  Shaoyi Sun ,  Mehran Seid Bagherzadeh ,  Vandna Raina ,  Duanjie Hou ,  Sultan Chowdhury ,  Shifeng Liu ,  Vishnumurthy Kodumuru ,  Nagasree Chakka

IPC: A61K31/501 ,  A61K31/445 ,  A61P3/00 ,  A61P3/10 ,  C07D237/02 ,  C07D401/04 ,  C07D211/94 ,  A61P3/04 ,  A61K31/50

CPC classification number: C07D213/82 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04

Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8, and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Abstract translation: 公开了在哺乳动物，优选人中治疗SCD介导的疾病或病症的方法，其中所述方法包括向有需要的哺乳动物施用式（I）化合物：式（I）其中x，y，G ，J，L，M，V，W，R 2，R 3，R 4，R 5， R 5a，R 6，R 6a，R 7，R 7a， R 8，R 8a和R 8a在本文中定义。 还公开了包含式（I）化合物的药物组合物。

公开(公告)号：US07030221B2

公开(公告)日：2006-04-18

申请号：US10151003

申请日：2002-05-21

Applicant: Rajender Kamboj ,  Candace E. Elliott ,  Stephen L. Nutt

Inventor： Rajender Kamboj ,  Candace E. Elliott ,  Stephen L. Nutt

IPC: C07K14/705

CPC classification number: C07K14/705 ,  C07K14/70571

Abstract: Described herein are isolated polynucleotides which code for a family of AMPA-type human CNS receptors. The receptors are characterized structurally and the construction and use of cell lines expressing these receptors are disclosed.

公开(公告)号：US06482609B1

公开(公告)日：2002-11-19

申请号：US09582200

申请日：2000-07-28

Applicant: Donald G. Munroe ,  Rajender Kamboj ,  Diana Peters ,  Fatemch Kooshesh ,  Tejal B. Vyas ,  Ashwani K. Gupta

Inventor： Donald G. Munroe ,  Rajender Kamboj ,  Diana Peters ,  Fatemch Kooshesh ,  Tejal B. Vyas ,  Ashwani K. Gupta

IPC: C12N1512

CPC classification number: C07K14/705 ,  A61K38/00

Abstract: A lysolipid receptor, a human EDG-4 receptor, a method of identifying lysolipid receptors involved in inflammatory response and the lysolipid receptors so identified, and a method of identifying ligands which interact with such lysolipid receptors.

Abstract translation: 溶血素受体，人EDG-4受体，鉴定参与炎症反应的溶脂性受体的方法和如此鉴定的溶脂型受体，以及鉴定与这种脂质性受体相互作用的配体的方法。

公开(公告)号：US06406868B1

公开(公告)日：2002-06-18

申请号：US08216326

申请日：1994-03-23

Applicant: Rajender Kamboj ,  Candace E. Elliott ,  Stephen L. Nutt

Inventor： Rajender Kamboj ,  Candace E. Elliott ,  Stephen L. Nutt

IPC: G01N33567

CPC classification number: C07K14/70571 ,  C07K14/705

Abstract: Described herein are isolated polynucleotides which code for an AMPA-type human CNS receptor, designated the human GluR1B receptor. The receptor is characterized structurally and the construction and use of cell lines expressing the receptor is disclosed.

Abstract translation: 本文描述了编码AMPA型人CNS受体的分离的多核苷酸，其命名为人GluR1B受体。 该受体的结构特征在于，公开了表达受体的细胞系的构建和用途。

公开(公告)号：US06391566B1

公开(公告)日：2002-05-21

申请号：US08264578

申请日：1994-06-23

Applicant: Robert L. Foldes ,  Sally-Lin Adams ,  Rajender Kamboj

Inventor： Robert L. Foldes ,  Sally-Lin Adams ,  Rajender Kamboj

IPC: G01N33567

CPC classification number: C07K14/705 ,  C07K14/70571 ,  G01N33/567 ,  G01N33/68

Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. This neurotransmission has been found to be modulated by certain modulatory proteins. DNA coding for a family of such modulatory proteins has now been isolated and the modulatory proteins have been characterized. Herein described are recombinant cell lines which produce these modulatory proteins as heterologous membrane-bound products. Also described are related aspects of the invention, which are of commercial significance, including the use of cell lines which express the modulatory proteins either homomerically, or hotoromorically in a complex with an NMDA receptor, as a tool for discovery of compounds which affect the function of the modulatory proteins.

Abstract translation: 兴奋性氨基酸（EAAs）如谷氨酸的神经传递通过膜结合表面受体介导。 已经发现这种神经传递被某些调节蛋白调节。 已经分离了编码这种调节蛋白家族的DNA，并且已经表征了调节蛋白质。 本文描述了产生这些调节蛋白作为异源膜结合产物的重组细胞系。 还描述了具有商业意义的本发明的相关方面，包括使用在与NMDA受体复合物中同源或热反式表达调节蛋白的细胞系作为影响功能的化合物的发现工具 的调节蛋白。

公开(公告)号：US06333161B1

公开(公告)日：2001-12-25

申请号：US08178019

申请日：1994-01-06

Applicant: Rajender Kamboj ,  Candace E. Elliott ,  Stephen L. Nutt

Inventor： Rajender Kamboj ,  Candace E. Elliott ,  Stephen L. Nutt

IPC: C12N1563

CPC classification number: C07K14/70571 ,  F02B2075/027

Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors of the kainate-binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein described are recombinant cell lines which produce the EAA receptor as a heterologous membrane-bound product. Also described are related aspects of the invention, which are of commercial significance. Included is use of the cell lines as a tool for discovery of compounds which modulate EAA receptor stimulation.

Abstract translation: 兴奋性氨基酸（EAAs）如谷氨酸的神经传递通过膜结合表面受体介导。 已经分离了编码红藻氨酸结合型EAA受体的这些受体的一个家族的DNA，并且以受体蛋白为特征。 本文描述了产生作为异源膜结合产物的EAA受体的重组细胞系。 还描述了具有商业意义的本发明的相关方面。 包括使用细胞系作为发现调节EAA受体刺激的化合物的工具。

公开(公告)号：US6040175A

公开(公告)日：2000-03-21

申请号：US483327

申请日：1995-06-07

Applicant: Rajender Kamboj ,  Candace E. Elliott ,  Stephen L. Nutt

Inventor： Rajender Kamboj ,  Candace E. Elliott ,  Stephen L. Nutt

IPC: C07K14/705 ,  C12N15/12 ,  C12N5/10

CPC classification number: C07K14/70571 ,  C07K14/705

Abstract: Described herein are isolated polynucleotides which code for an AMPA-type human CNS glutamate receptor, designated the human GluR2B receptor. The receptor is characterized structurally and the construction and use of cell lines expressing these receptor is disclosed.

Abstract translation: 本文描述了编码AMPA型人CNS谷氨酸受体的分离的多核苷酸，其命名为人GluR2B受体。 该受体的结构特征在于，公开了表达这些受体的细胞系的构建和用途。